Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AHR | P35869 | 5/20 | 0.56 |
| ▸ | CYP1B1 | Q16678 | 1/20 | 0.48 |
| ▸ | SLC6A3 | Q01959 | 6/20 | 0.47 |
| ▸ | SLC6A2 | P23975 | 3/20 | 0.46 |
| ▸ | HPGD | P15428 | 2/20 | 0.46 |
| ▸ | MEN1 | O00255 | 1/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.43 |
| ▸ | MAPT | P10636 | 1/20 | 0.43 |
| ▸ | HTT | P42858 | 1/20 | 0.43 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.43 |
| ▸ | PTGS2 | P35354 | 2/20 | 0.42 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.42 |
| ▸ | POLB | P06746 | 1/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.41 |
| ▸ | NPC1 | O15118 | 1/20 | 0.39 |
| ▸ | RAB9A | P51151 | 1/20 | 0.39 |
| ▸ | TP53 | P04637 | 1/20 | 0.39 |
| ▸ | NOTUM | Q6P988 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6472818 | 0.93 | AHR (0.59) | AHRCYP1B1SLC6A3SLC6A2HPGD | |
| SCHEMBL9870874 | 0.88 | AHR (0.65) | AHRCYP1B1SLC6A3SLC6A2HPGD | |
| SCHEMBL19993855 | 0.81 | SLC6A3 (0.40) | AHRSLC6A3SLC6A2NPSR1PTGS2 | |
| SCHEMBL19993948 | 0.81 | PTGS2 (0.46) | SLC6A3SLC6A2NPSR1PTGS2PTGS1 | |
| SCHEMBL12473824 | 0.78 | AHR (0.52) | AHRCYP1B1SLC6A3HPGDMEN1 | |
| SCHEMBL27997002 | 0.78 | AHR (0.52) | AHRCYP1B1SLC6A3SLC6A2HPGD | |
| SCHEMBL28845071 | 0.77 | AHR (0.45) | AHRCYP1B1SLC6A3SLC6A2HPGD | |
| SCHEMBL27309004 | 0.77 | CYP2A6 (0.45) | AHRHPGDMEN1KMT2AALDH1A1 | |
| SCHEMBL19993941 | 0.77 | PTGS2 (0.51) | MEN1KMT2AALDH1A1MAPTPTGS2 | |
| SCHEMBL21700368 | 0.75 | AHR (0.48) | AHRCYP1B1SLC6A3SLC6A2HPGD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-101394847-B | Cycloalkylamines as monoamine reuptake inhibitors | 塞普拉柯公司 | 2017-05-24 | — | — | CN | claimed |
| CN-103140476-A | Novel trpv3 modulators | ABBOTT LAB | 2013-06-05 | — | — | CN | claimed |
| US-7037931-B2 | Corticotropin releasing factor moderator; analgesics; drug abruse, drug dependency; schizophrenia | JANSSEN PHARMACEUTICA N.V. (BE) | 2006-05-02 | — | — | US | claimed |
| JP-2006501194-A | — | — | 2006-01-12 | — | — | JP | claimed |
| EP-1525190-A1 | CCK-1 RECEPTOR MODULATORS | JANSSEN PHARMACEUTICA N.V. (BE) | 2005-04-27 | — | — | EP | claimed |
| WO-2004007463-A1 | CCK-1 RECEPTOR MODULATORS | JANSSEN PHARMACEUTICA, N.V. (BE) | 2004-01-22 | — | — | WO | claimed |
| CN-101394847-B | Cycloalkylamines as monoamine reuptake inhibitors | 塞普拉柯公司 | 2017-05-24 | — | — | CN | disclosed |
| CN-104254522-A | Methanol derivatives as trpv3 modulators | ABBVIE INC | 2014-12-31 | — | — | CN | disclosed |
| CN-103140476-A | Novel trpv3 modulators | ABBOTT LAB | 2013-06-05 | — | — | CN | disclosed |
| US-7465808-B2 | CCK-1 receptor modulators | JANSSEN PHARMACEUTICA, N.V. (BE) | 2008-12-16 | — | — | US | disclosed |
| US-7037931-B2 | Corticotropin releasing factor moderator; analgesics; drug abruse, drug dependency; schizophrenia | JANSSEN PHARMACEUTICA N.V. (BE) | 2006-05-02 | — | — | US | disclosed |
| US-20060014817-A1 | CCK-1 receptor modulators | JANSSEN PHARMACEUTICA, N.V. (BE) | 2006-01-19 | — | — | US | disclosed |
| US-20060004195-A1 | Alpha,beta-unsaturated esters and acids by stereoselective dehydration | JANSSEN PHARMACEUTICA N.V. (BE) | 2006-01-05 | — | — | US | disclosed |
| US-20050026903-A1 | CCK-1 receptor modulators | JANSSEN PHARMACEUTICA N.V. (BE) | 2005-02-03 | — | — | US | disclosed |
| US-20050020565-A1 | Pyrazole compound; gastrointestinal disorders; central nervous system disorders | JONES TODD K (US) | 2005-01-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050020565-A1 | Pyrazole compound; gastrointestinal disorders; central nervous system disorders | CCKAR, CCKBR, NPY1R | AHR 16/4885CYP1B1 206/4885SLC6A3 824/4885 |
| US-20060014817-A1 | CCK-1 receptor modulators | CCKAR, CCKBR, GIPR | AHR 566/4885CYP1B1 942/4885SLC6A3 2192/4885 |
| US-20060004195-A1 | Alpha,beta-unsaturated esters and acids by stereoselective dehydration | CCKAR, CCKBR, FFAR1 | AHR 141/4885CYP1B1 312/4885SLC6A3 2319/4885 |
| US-20050026903-A1 | CCK-1 receptor modulators | CCKAR, CCKBR, GLP1R | AHR 28/4885CYP1B1 322/4885SLC6A3 2793/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.